# Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

> **NCT02906670** · PHASE1,PHASE2 · TERMINATED · sponsor: **Symphogen A/S** · enrollment: 32 (actual)

## Conditions studied

- Oncology

## Interventions

- **DRUG:** Sym013

## Key facts

- **NCT ID:** NCT02906670
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-01
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02906670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02906670, "Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02906670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*